 Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents |
| OF THE INVENTION Usually, in the method of synthesis of the radiolabelled platinum ... |
|
| Pharmaceutical composition for diabetic neuropathy |
| What is claimed is: 1. A method for the prophylaxis of diabetic peripheral neuropathy, which ... |
|
| Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance |
| This invention aids in fulfilling this need in the art by providing an in vitro, single cycle, ... |
|
| Compositions and methods for sensitive detection of HIV infection and monitoring of drug resistance |
| OF THE INVENTION The present invention relates to new and useful methods including methods for ... |
|
| Continuous process for ethanol production by bacterial fermentation |
| The accompanying FIGURE will provide a background for the following discussion in which the method ... |
|
| Stable solution of hyaluronate in a balanced salt medium |
| What is claimed is: 1. A physiological visco-elastic formulation consisting of sodium hyaluronate ... |
|
| Radiolabeled fusion toxins for cancer therapy |
| The present invention describes the synthesis and purification of a new class of compounds known as ... |
|
| Genetically modified cells expressing a TGF.beta. inhibitor, the cells being lung cancer cells |
| OF THE PREFERRED EMBODIMENT Lung cancers account for 30% of all death due to cancer in the United S... |
|
| Auto-ligating oligonucleotide compounds |
| OF THE INVENTION The invention relates to a method and compositions for in situ formation of an ... |
|
| Nucleic acids encoding transcription factor APRF (acute phase response factor) |
| What is claimed: 1. An isolated DNA molecule which encodes a human APRF polypeptide having the ... |
|
|
Enhancing agent for nerve growth factor production comprising a compound having a coumarin backbone or a compound having a 2-dimethyl chroman backbone
| Details |
Inventors: Ohnogi, Hiromu; Shiraga, Masahiro; Sagawa, Hiroaki; Kato, Ikunoshin;
Assignee: Takara Bio, Inc. (Otsu, JP)
Primary Examiner: Peselev; Elli
Assistant Examiner:
Attorney, Agent or Firm: Birch, Stewart, Kolasch & Birch, LLP
The present invention relates to a medicament, a food, a beverage or a feed, each comprising as an effective ingredient a compound having an enhancing action for NGF production, which is effective for a treatment, an amelioration of symptom, prevention or the like of a disease requiring enhancement of NGF production, wherein the compound has a coumarin and/or chroman backbone. Since no toxicity is especially found in the effective ingredient of the present invention, and there is no risk of incidence of adverse actions, the treatment or the like of the above disease can be safely and appropriately carried out. |
|
DETAILED DESCRIPTION The invention claimed is: 1.
A therapeutic agent or prophylactic agent for a disease requiring enhancement of nerve growth factor production, wherein the therapeutic agent or prophylactic agent comprises as an effective ingredient at least one isolated or purified compound selected from the group consisting of 7-O-.
beta.
-D-glucopyranosyloxy-8-prenyl coumarin, 7-.
beta.
-D-glucopyranosyloxy-6-prenyl coumarin, 3'-O-.
beta.
-D-glucopyranoyl khellactone, 4'-O-angeloyl-3'-O-[6-O-(.
beta.
-D-glucopyranosyl)-.
beta.
-D-glucopyranosyl- ]-khellactone, a compound represented by the general formula (III): ##STR00006## wherein R.
sub.
6 is a hydrogen atom, hydroxyl group, carboxyl group, an aliphatic group, an aromatic group, an aromatic-aliphatic group or a saccharide residue, and pharmacologically acceptable salts thereof and optionally in combination with a pharmaceutically acceptable carrier.
2.
The therapeutic agent or prophylactic agent according to claim 1, wherein the compound represented by the general formula (III) is 8-carboxyl-3-hydroxy-5-methoxy-2-dimethyl chroman or 3-hydroxy-8-[3-(4-hydroxyphenyl)-acryloyl]-5-methoxy-2-dimethyl chroman.
3.
An enhancing agent for nerve growth factor production, wherein the agent comprises as an effective ingredient at least one isolated or purified compound selected from the group consisting of 7-O-.
beta.
-D-glucopyranosyloxy-8-prenyl coumarin, 7-.
beta.
-D-glucopyranosyloxy-6-prenyl coumarin, 3'-O-.
beta.
-D-glucopyranoyl khellactone, 4'-O-angeloyl-3'-O-[6-O-(.
beta.
-D-glucopyranosyl)-.
beta.
-D-glucopyranosyl- ]-khellactone, a compound represented by the general formula (III): ##STR00007## wherein R.
sub.
6 is a hydrogen atom, hydroxyl group, carboxyl group, an aliphatic group, an aromatic group, an aromatic-aliphatic group or a saccharide residue, and pharmacologically acceptable salts thereof.
4.
The agent according to claim 3, wherein the isolated or purified compound represented by the general formula (III) is 8-carboxyl-3-hydroxy-5-methoxy-2-dimethyl chroman or 3-hydroxy-8-[3-(4-hydroxyphenyl)-acryloyl]-5-methoxy-2-dimethyl chroman
|
| Related patents |
|
|
In vitro packaging of adeno-associated virus DNA
It is an object of the present invention to provide a method for packaging a DNA substrate in an in vitro reaction to produce adeno-associated virus (AAV) particles ...
|
|
|
Recombinant viral vector system
The present invention relates to the in vitro synthesis of a novel 165 basepair fragment of DNA which contains AAV ITR sequences and which can be synthesized in vitro ...
|
|
|
Modified adeno-associated virus vector capable of expression from a novel promoter
This invention provides an adeno-associated viral vector comprising the inverted terminal repeat sequences of adeno-associated virus and a nucleic acid, wherein the ...
|
|
|
Culturable mitochondrial cells with no nucleus, showing mitochondrial activity
OF THE INVENTION Hereinafter, the present invention will be described in detail. (1) Method of Producing the Cells of the Present Invention The present invention ...
|
|
|
Antisense oligonucleotides inhibiting human bcl-2 gene expression
The invention provides oligodeoxynucleotides and methods for inhibiting growth of lymphoma or leukemia cells, that are types of lymphocytes. An antisense ...
|
|
|
Process for the synthesis of oligomeric compounds
What is claimed is: 1. A method for the preparation of an oligomeric compound having a moiety of Formula I: ##STR38## wherein: X.sub.4 is Z or H; Z is CN, halogen, ...
|
|
|
Process for oligonucleotide synthesis
OF THE PREFERRED EMBODIMENTS The present invention is directed to methods for linking a phosphoramidite nucleoside to a solid support-bound nucleoside. These methods ...
|
|
|
Derivatized oligonucleotides having improved uptake and other properties
OF THE INVENTION Antisense therapeutics can be practiced in a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular ...
|
|
|
Process for the synthesis of oligomeric compounds
What is claimed is: 1. A compound having the formula: ##STR38## wherein: X.sub.4 is Z or H; Z is CN, a halogen radical, , alkaryl, substituted sulfoxyl, substituted ...
|
|
|
Processes for the synthesis of oligomeric compounds
OF PREFERRED EMBODIMENTS The present invention provides methods for the preparation of oligomeric compounds having at least one phosphodiester or phosphorothioate ...
|
|
|
Gene Therapy 
